These co-morbidities are characterized by hyperinsulinemia, hyperglycemia, and increased expression of IGF-I and -II that have each been associated with poor prognosis and more aggressive cancers that exhibit increased metabolism and increased glucose uptake (13–15). This evidence concerns the gene IGF1 and hyperinsulinism.